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ABSTRACT 
BACKGROUND: Graves’ disease is routinely treated with antithyroid drugs (ATD), 
radioactive-iodine (RAI), or surgery but it is uncertain whether the choice of initial 
therapy influences long-term outcomes. We evaluated cardiovascular morbidity and 
mortality according to the modality and effectiveness of primary therapy in Graves’ 
disease. 
METHODS: The study was conducted through linked datasets within the All-Wales 
Secure Anonymised Information Linkage (SAIL) Databank. Graves’ disease patients 
were identified from a regional TSH-receptor-antibody test register, (n=4,189, female 
82%, 1998–2013) and matched by age and sex to a control population in SAIL 
(n=16,756). Patients were grouped by treatment within one-year of diagnosis as: (1) 
ATD (n=3587), (2) RAI with resolved hyperthyroidism (RAI-Group-A, n=250), and (3) 
RAI with unresolved hyperthyroidism (RAI-Group-B, n=182). One-year landmark 
Kaplan-Meier and Cox regression models were used to analyse the association of 
treatment with all-cause mortality and major adverse cardiovascular events (MACE, 
myocardial infarction, heart failure, ischaemic stroke, or death). The relationship 
between FT4 concentration and outcomes was analysed using restricted cubic-
spline regression models. 
FINDINGS:  Overall, patients had increased mortality compared to controls (HR 
1·23, 95%CI 1·06, 1·42). Compared to ATD-treated patients, mortality was reduced 
in RAI-Group-A (HR 0·50, 95%CI 0·29, 0·85) but not RAI-Group-B (HR 1·51, 95%CI 
0·96, 2·37). Persistently low-TSH at 1-year was associated with increased mortality 
independent of treatment modality (HR 1·55, 95%CI 1·08-2·24). Spline-regressions 
demonstrated a positive non-linear relationship between 1-year-FT4 and outcomes. 
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INTERPRETATION: 	Regardless of therapy modality, early and effective control of 
Graves’ hyperthyroidism is associated with improved survival compared to less 
effective control.  
FUNDING: National Institute for Social Care and Health Research (NISCHR), Wales 
  
4	
	
RESEARCH IN CONTEXT  
Evidence before this study 
We searched PubMed for articles published up to October 2018, without language 
restrictions, that addressed mortality outcomes in relation to treatment modality in 
patients with hyperthyroidism. Our search terms were (“hyperthyroidism” OR 
“thyrotoxicosis” OR “Graves’ disease”) AND (“mortality” OR “survival”) AND 
(“treatment” OR “antithyroid drugs” OR “thionamides” OR “radioactive iodine” OR 
“thyroidectomy”). Although several studies reported excess mortality in radioiodine-
treated cohorts, these studies did not include patients treated with antithyroid drugs 
which currently represents the predominant therapy modality for Graves’ disease 
worldwide. Only one study to date has compared hyperthyroidism mortality 
according to treatment with antithyroid drugs or radioiodine. This study showed 
survival advantages following radioiodine-induced hypothyroidism compared to 
during antithyroid drug treatment. However, the study comprised a heterogeneous 
hyperthyroid cohort that was underpowered to show treatment effects in the Graves’ 
disease subset of 345 patients. 
Added value of this study 
To the best of our knowledge ours is the first study to show that early and complete 
resolution of hyperthyroidism in patients with Graves’ disease is associated with 
improved survival compared to less effective control. We show that survival in 
patients with Graves’ disease is associated with the rapid restoration of normal 
thyroid status rather than therapy modality per se. Using flexible spline regression 
modelling we demonstrate a positive association between FT4 levels after initial 
therapy and subsequent cardiovascular morbidity and mortality.  
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Implications of all the available evidence 
Our findings emphasise the importance of prompt elimination of hyperthyroidism and 
maintenance of normal thyroid status in the care of Graves’ disease patients. The 
choice of therapy should be driven by the prospects of successful resolution of 
hyperthyroidism and therefore, early definitive therapy should be offered to patients 
unlikely to achieve remission with antithyroid drugs alone. 
 
  
6	
	
INTRODUCTION 
Graves’ disease is the most common cause of hyperthyroidism in iodine-sufficient 
countries, affecting 0·5–1.0% of the population1,2. Hyperthyroidism in Graves’ 
disease results from unregulated stimulation of the thyrotropin (TSH) receptor by 
autoreactive TSH-receptor antibodies (TRAbs) which are detectable in virtually every 
patient with the disease3. Patients with uncorrected hyperthyroidism have an 
increased mortality risk and suffer significant cardiovascular morbidity including 
cardiac arrhythmias, strokes and heart failure4,5. Three treatment modalities for 
Graves’ disease, namely thionamide drugs, radioactive iodine, and thyroidectomy 
have been available for decades, all with established safety and efficacy records. 
However, the approach to therapy is highly variable and largely dictated by regional 
preferences2,6. Primary thionamide therapy is favoured by the European Thyroid 
Association7, while the American Thyroid Association endorses any of the modalities 
depending on individual patient characteristics8. In practice radioiodine is traditionally 
preferred in North America9 although antithyroid drugs are increasingly used and are 
now the most common treatment for Graves’ disease in the United States 10. In 
contrast primary radioiodine therapy is less popular in Europe and Asia and remains 
restricted to patients who relapse following 12-18 months of thionamides112.  
These variations in treatment are in part driven by lack of evidence regarding 
mortality risk with respect to Graves’ disease management. Randomised controlled 
trials on mortality outcomes in Graves’ disease are lacking and are unlikely to be 
undertaken given the logistic implications. Although observational studies have 
addressed mortality end-points in patients with hyperthyroidism4,12-18, only a few 
studies specifically distinguished Graves’ disease from other causes of 
hyperthyroidism17,19-23. This distinction is relevant given that Graves’ disease patients 
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are younger and express a different cardiovascular phenotype from those with 
thyroid nodules2,5,20,22. In addition, unlike patients with toxic nodules who require 
definitive treatment for cure, Graves’ disease patients have a choice of all three 
treatments, underpinning the need for treatment-specific outcome data. 
Although previous cohort studies have reported excess mortality in radioiodine-
treated patients15,17,18,23,24, these cohorts excluded patients treated with thionamides 
which currently represents the predominant therapy modality for Graves’ disease 
worldwide2. Only one study to date has compared mortality according to thionamide 
versus radioiodine treatment19. The study by Boelaert et al observed reduced 
mortality after radioiodine induced hypothyroidism compared to during thionamide 
therapy. However, the study comprised a heterogeneous hyperthyroidism clinic 
cohort (n=1036) that was underpowered to show treatment effects in the Graves’ 
disease subset (n=345)19. Thus, it remains unclear whether primary radioiodine 
therapy offers survival advantages over thionamides and hence whether current 
Graves’ disease treatment strategies are optimal. Our objective in the present study 
was to evaluate cardiovascular morbidity and mortality according to the modality and 
effectiveness of primary therapy in a large cohort of patients with Graves’ disease.  
METHODS 
Data Sources and study population  
The study was conducted through linked datasets within the Secure Anonymised 
Information Linkage (SAIL) Databank. SAIL is a nationwide repository of routinely 
collected health and social care data in Wales run by the Health Informatics 
Research Unit of Swansea University. The databank contains over two billion 
anonymised person-based records linked to hospital admission and primary care 
data25. All National Health Service (NHS) users in Wales are identified by a unique 
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10-digit identifier and anonymity of data within the databank is ensured by multi-party 
encryption through a split-file data management system26. For this study, we created 
a dataset of patients with hyperthyroidism, diagnosed between January 1998 and 
December 2013 in clinics across three health boards serving an estimated 1·4 
million residents in South Wales. We included all patients who could be linked to the 
Welsh Demographic Service, a population register of individuals registered with a 
general practitioner (GP) or receiving healthcare in Wales. Additional outcomes were 
obtained from primary care data held within SAIL, covering about 75% of the 
population, and the Patient Episode Database for Wales (PEDW), a dataset of all 
inpatient admissions in Wales.  
Patients with Graves’ disease were identified from electronic records of TRAb tests 
performed at the biochemistry department of the University Hospital of Wales, 
Cardiff, which served as the regional TRAb-assay laboratory during the period 
covered by the study. TRAbs are sensitive and specific markers of Graves’ disease27 
and are routinely included in the diagnostic work-up of Graves’ disease in our 
catchment clinics. Patients were defined as Graves’ Hyperthyroidism if they had a 
positive TRAb test together with evidence of hyperthyroidism from either: (a) low-
TSH in laboratory records, (b) record of hyperthyroidism in GP or hospital datasets 
(ICD-10 E05, read codes C02), or (c) record of thionamide prescription in GP data 
(carbimazole, read codes fa1 and propylthiouracil, fa2). The patient inclusion flow 
chart is presented in figure 1. For a background control population, we identified a 
sample of individuals in the Welsh Demographic Service, matched to cases on birth 
week and sex, at a ratio of 4 control subjects per patient (n=16,756). Individuals with 
hyperthyroidism on our loaded datasets were excluded from the controls.  
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Treatment and outcome data 
Iodine-131 treatment data was extracted from radioiodine treatment logs in nuclear 
medicine departments serving the study population. Each department holds statutory 
records of all radioisotope treatment including isotope type, dose, and date of 
administration. Information on thyroidectomy was obtained from PEDW using the 
Office of Population censuses and Surveys version 4 (OPCS-4) classification code 
for thyroidectomy, B081-B091. Outcome events were recorded from PEDW using 
the relevant ICD-10 codes for atrial fibrillation (I48), acute myocardial infarction (I21-
I23), acute coronary syndrome (I20), heart failure (I50), ischaemic stroke (I63, I65-
I68), haemorrhagic stroke (I60-I62), diabetes mellitus (E10-E14), thyroid cancer 
(C73), and breast cancer (C50). Mortality information was obtained from the Office 
for National Statistics (ONS). 
Laboratory assays 
TRAbs were performed with second generation radioimmunoassays while thyroid 
hormones (FT4 and TSH) were performed using several different immunoassays. 
The laboratory assays, reference ranges and performance measures are detailed in 
the supplementary appendix and supplementary table 1. 
Statistical analysis 
Baseline data is summarised as means (standard deviation, SD) for normally 
distributed values or median (interquartile range, IQR) for non-normal data. 
Differences between groups were analysed with chi-squared test, 2-tailed t-test or 
Mann-Whitney tests as appropriate. The primary study outcome was all-cause 
mortality while secondary outcome was major adverse cardiovascular events 
(MACE), a composite of acute myocardial infarction, ischaemic stroke, heart failure, 
or death. Patients were grouped according to primary treatment using a landmark 
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approach to avoid immortal time bias. The landmark was set at one-year post-
diagnosis which was considered sufficient time for primary therapy without incurring 
excessive data losses from pre-landmark censoring.  
Treatment groups comprised: (1) ATD, patients who received only antithyroid drugs 
in the first year of diagnosis, (2) RAI-Grp-A, patients who received radioiodine and 
achieved hyperthyroidism control by one-year, and (3) RAI-Grp-B, patients who 
received radioiodine but had not achieved hyperthyroidism control by one-year. We 
excluded patients if they were censored before one-year (n=93) or had 
thyroidectomy in the first-year due to small numbers (78 patients, 2 deaths). Control 
of hyperthyroidism after radioiodine was defined as levothyroxine initiation, or TSH 
above the reference limit, or persistent euthyroidism (>6 months), each without 
antithyroid drug use. The diagnosis date was the date of the first positive TRAb or 
low-TSH, whichever was recorded earlier, and follow-up was from diagnosis until 
event or study end.  
We analysed outcomes according to primary treatment using Kaplan-Meier curves 
and Cox regression models. First, we compared event rates in patients and 
population controls using the logrank test and an adjusted Cox regression model to 
account for baseline comorbidity. The analysis was undertaken in the whole cohort 
and stratified by primary treatment group, with the corresponding matched 
population for each group as controls. In a second approach, we used a Cox 
regression model to compare event risk between treatment groups with the 
antithyroid drug group as reference category. Models were adjusted for 5-year age 
bands, gender, diagnosis-year, baseline TRAb concentration, and comorbidity 
scores, using a modification of the Charlson Comorbidity Index (supplementary table 
2). Stratified analysis was undertaken by age (>50 vs. <50 years) and co-morbidity 
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score (0 vs >1) with interaction terms for sub-groups. In sensitivity analysis, we 
sequentially excluded pregnant patients (n=63) and patients with borderline TRAb 
levels (n=266) at diagnosis. The validity of the proportional hazard assumption was 
examined by Schoenfeld residuals test and visual inspection of residuals plots 
against time.  
As an alternative means of handling time bias, treatment and thyroid status were 
incorporated as time-dependent covariates in a multivariable Cox proportional 
hazard regression model in which patients contributed person-time as follows: (1) 
ATD, from diagnosis to definitive treatment with radioiodine or thyroidectomy; (2) RAI 
without hyperthyroidism control, from radioiodine therapy until control of 
hyperthyroidism, (3) RAI with hyperthyroidism control, following radioiodine control of 
hyperthyroidism; (4) Thyroidectomy, following thyroidectomy.  
To directly evaluate the impact of thyroid status, we analysed outcomes according to 
thyroid function after one-year of treatment. We derived a one-year FT4 and TSH 
from time-weighted averages of all available tests at 9–12 months excluding patients 
censored before one-year. TSH was entered in a Cox regression model as low, 
normal, or high-TSH with the normal-TSH as reference category. Models were 
adjusted for age, gender, comorbidity, baseline TRAb, FT4 and TSH, and then 
stratified by primary treatment modality based on treatment received by the test date. 
For FT4, we used restricted cubic splines to model a possible non-linear relationship 
between one-year FT4 and outcomes. Four equally-spaced knots were set at 
percentiles 5, 35, 65 and 95 according to Harrell’s recommendation28. To account for 
differences in assay methods, FT4 was converted to multiples of the upper limit of 
the assay reference range (ULN). Restricted cubic splines were also used to model 
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the longitudinal FT4 change in in the first 24-months of treatment with cubic knots set 
at 0, 3, 6, 9, 12, and 18 months.  
Serial thyroid function tests were missing in 29% of patients. The characteristics of 
patients with thyroid tests were comparable to those with missing tests except that 
patients with tests were younger (mean age 47 vs 49 years, P<0.001), and missing 
tests were more frequent in patients treated with antithyroid drugs compared to 
radioiodine or surgery (37% vs 3% vs 16%, P<0.001) (supplementary appendix, 
supplementary table 3). Thus, we addressed missing tests in the one-year TSH 
analysis using multiple variable imputation by chained equations29 under the missing 
at random assumption (supplementary appendix). We generated 50 imputed 
datasets with 500 iterations and fitted Cox proportional models within each dataset 
after which estimates were pooled according to Rubin’s rules. Sensitivity analysis 
using a complete case analysis gave similar results, so we report results from the 
imputed datasets while the complete case analysis is presented in the 
supplementary appendix. Statistical analysis was performed via remote desktop with 
the SAIL Databank using Stata version 16 for Windows (Stata Corp., College 
Station, TXS, USA).  
Regulatory Approvals 
The study was registered with the Research and Development Office of Cwm Taf 
Health Board and approval for data linkage with individual health boards was 
obtained (reference CT/688/140049/16). Approval for access to anonymised data in 
the SAIL databank was granted by the SAIL Information Governance Review panel 
(project reference, 0233). Ethical permission is granted for conducting data analysis 
in the SAIL Databank and separate ethics committee review was not required for this 
study.  
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Role of the funding source 
The funding source had no role in study design, data analysis, or writing of the 
report. The corresponding author had full access to all the data in the study and had 
final responsibility for the decision to submit for publication. 
RESULTS 
The final study cohort comprised 4,189 TRAb-positive patients with Graves’ disease 
and 16,756 controls, with follow-up ranging from 6 months to 16·8 years in the SAIL 
databank. Baseline characteristics are presented in table 1. 82% of patients were 
females with peak age 30–60 years. Overall, antithyroid drug treatment alone was 
used in 74% of patients while 20% and 6% received radioiodine or thyroidectomy 
respectively. Of the whole cohort, 4,019 patients with at least one-year follow-up 
were eligible for inclusion in the landmark analysis including 3,587 patients treated 
with antithyroid drugs (ATD) alone in the first-year, 250 radioiodine-treated patients 
with resolved hyperthyroidism by one-year (RAI-Grp-A), and 182 radioiodine-treated 
patients with unresolved hyperthyroidism by one-year (RAI-Grp-B). The 
characteristics of the landmark cohort is presented in Supplementary table 4. As in 
the full cohort, radioiodine treated patients were older than medically-treated patients 
(mean age 53 vs 47 years) and had more severe disease at diagnosis in terms of 
higher baseline levels of FT4 and TRAbs than ATD patients. Although both 
radioiodine groups were well-balanced in baseline characteristics and iodine-131 
dose (median 555 Mbq), RAI-Grp-A patients received earlier iodine-131 treatment 
than RAI-Grp-B (median time to treatment of 108 vs 188 days).  
Overall, 228 deaths (5·4%) were recorded in patients compared to 765 (4·6%) in 
controls. Crude and adjusted Cox regression models for mortality and other events 
are presented in table 2. Patients had increased mortality (HR 1·23, 95%CI 1·06, 
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1·42) and MACE (HR 2·47, 95%CI 2·16, 2·81) compared to controls and also had 
increased risks for atrial fibrillation, congestive cardiac failure, and ischaemic stroke 
(table 2). Figure 2 shows survival curves in patients versus controls, presented for 
the whole cohort and stratified by primary treatment groups. The adjusted Cox 
regression model showed an increase in mortality and MACE in all treatment groups 
apart from RAI-Grp-A patients (HR 0·65, 95%CI 0·38, 1·13). Logrank tests gave 
consistent results with the adjusted model except for mortality in RAI-Grp-B (figure 
2d) and MACE in RAI-Grp-A (figure 2g) which failed to reach significance by logrank 
but were significant in the adjusted model. The results remained unchanged when all 
treatment groups and the control population were included in an adjusted Cox 
regression model with a shared frailty term for case-control clusters. 
Between-group comparisons are shown in figure 3. RAI-Grp-A patients had reduced 
risk of mortality (HR 0·50, 95% CI 0·29, 0·85) and MACE (HR 0·59, 95% CI 0·38, 
0·92) compared to the ATD group. In contrast, RAI-Grp-B patients had an increase 
in MACE risk (HR 1·52, 95% CI 1·01, 2·28) with no survival advantage over ATD 
patients. Similar results were seen in sub-groups without comorbidity but not those 
with comorbidity (P for interaction 0.039). There was no interaction with age (>50 vs 
<50 years) and results remained unchanged after excluding pregnant patients or 
patients with borderline TRAbs (supplementary tables 5 and 6).  
The results of the time-dependent multivariable analysis are presented in 
supplementary tables 7 and 8. The models incorporated serial thyroid hormones and 
treatment modality as time-dependent variables. Mortality and MACE risk increased 
with age, male gender, and co-morbidity but reduced with increasing year of 
diagnosis possibly reflecting temporal improvements in overall cardiovascular 
survival. Increased risk of mortality and MACE was observed with increasing levels 
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of serial FT4 but not serial TSH. With respect to treatment, reduced mortality and 
MACE risk was seen after radioiodine induced control of hyperthyroidism compared 
to during antithyroid drug therapy. In contrast reduced mortality was not seen after 
radioiodine therapy that had not controlled hyperthyroidism or after thyroidectomy 
although there was low power due to fewer thyroidectomies (supplementary table 7–
8).  
To evaluate the influence of thyroid status on outcomes we analysed the relationship 
of TSH at one-year with mortality and MACE using a landmark Cox regression model 
(figure 4). Of the patients with a one-year TSH, 898 (39%) had low-TSH while 429 
(19%) had high-TSH. The fully adjusted model showed increased mortality and 
MACE risk with Low-TSH but not high-TSH (figure 4). This association was observed 
in the whole cohort as well as in the antithyroid drug group with no significant 
interaction with treatment (P value for interaction of 0.325 and 0.565 for mortality and 
MACE respectively, figure 4). Similar results were obtained from the imputation 
model (figure 3) and the complete case analysis (supplementary figure 1).  
The relationship between FT4 and outcomes was modelled with restricted cubic 
splines which showed increasing hazard with FT4 concentrations above the 
reference range (figure 5). This relationship was seen in the whole cohort and in 
drug-treated patients but not radioiodine-treated patients (figure 5). Cubic splines 
were also used to model the longitudinal change in FT4 after diagnosis. All treatment 
groups showed a rapid drop in FT4 after diagnosis which was most pronounced and 
sustained in the successfully treated radioiodine group (supplementary figure 2).  
DISCUSSION 
We have used linked health records to evaluate all-cause mortality and 
cardiovascular event risk in patients with Graves’ disease and compared outcomes 
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according to the modality and effectiveness of primary treatment. Compared to 
population controls, Graves’ disease patients had a 23% increase in all-cause 
mortality and over twice the risk of a major cardiovascular event. Furthermore, early 
and successful treatment with radioiodine was associated with a 50% reduction in 
mortality compared to primary treatment with antithyroid drugs. Notably, survival 
advantages were not seen in radioiodine treated patients who failed to achieve 
control of hyperthyroidism. Patients with persistently low-TSH after one-year of 
treatment had a 55% increase in mortality even in patients treated with antithyroid 
drugs alone. Thus, for the first time, we show that mortality in patients with Graves’ 
disease is reduced by early and intensive correction of hyperthyroidism regardless of 
therapy modality. 
Our findings confirm the increased mortality risk previously reported in some19,20,22 
but not all17,30 hyperthyroidism outcome studies. However, only a few studies to date 
have specifically addressed mortality risk in relation to hyperthyroidism treatment. 
Previous large-scale cohort-studies suggested an excess of cardiovascular mortality 
in radioiodine-treated patients compared to the background population15,17,18,31. A 
1980s United States thyroid clinic study observed no difference in mortality between 
radioiodine and thyroidectomy-treated women32 whereas more recent registry 
studies from Finland 24 and Sweden23 have reported survival advantages of 
thyroidectomy over radioiodine treatment. The interpretation of these data is clearly 
constrained by study designs that excluded thionamide-treated 
patients15,17,18,23,24,31,32, failed to account for thyroid status23,31,32, and did not control 
for bias from uneven time-intervals preceding definitive therapy15,17,18,31,32. In their 
Birmingham clinic study, Boelaert et al applied a time-dependent regression model 
that incorporated thyroid status to show survival benefits relative to thionamides 
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following radioiodine-induced hypothyroidism19. However, their study was 
underpowered to show benefits in the Graves’ disease subset19.  
In the present study, we have employed a study design that distinguished treatment 
effects from the effects of hyperthyroidism to show that the predictor of 
cardiovascular morbidity and mortality is the effectiveness of primary treatment 
rather than therapy modality per se. Our one-year TSH analysis shows that the 
excess mortality in Graves’ disease is driven by exposure to uncontrolled 
hyperthyroidism and that elimination of the hyperthyroid state whether with 
antithyroid drugs or radioiodine yields survival benefits. This is biologically plausible 
given the established association of hyperthyroidism with cardiovascular disease4 
and is consistent with a recent Danish register-based study that reported excess 
mortality in association with cumulative periods of low-TSH in patients with treated 
and untreated hyperthyroidism14. Subsequent analyses of the Danish register also 
showed increased mortality with cumulative hypothyroidism exposure33 highlighting 
the need for strict surveillance of therapy to avoid periods of uncontrolled 
hypothyroidism or hyperthyroidism. As our data shows, persistent thyroid dysfunction 
is common during Graves’ disease therapy, with low or high TSH recorded in 58% of 
patients at one-year.  
The choice of primary therapy in Graves’ disease is currently driven by regional 
preferences7,8. Our findings indicate that a greater value should now be placed on 
the rapid elimination of hyperthyroidism with maintenance of a normal-TSH as 
standard of care. Thus, patients with unfavourable characteristics for thionamide-
induced relapse such as severe disease, or high TRAb levels should be offered 
primary radioiodine therapy. The use of radioiodine should be governed by treatment 
protocols designed to optimise treatment success through efficient patient 
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preparation and administration of ablative doses of iodine-131. Primary definitive 
treatment will not be a priority for patients with mild disease and in such cases 
thionamides should be used at doses and duration that promote rapid and sustained 
control of hyperthyroidism.  
The strength of our study is the unique dataset of 4,189 TRAb-positive Graves’ 
disease patients with long-term follow-up and robust and innovative data linkage. 
Ours is the first large-scale hyperthyroidism cohort study to exploit TRAbs as a 
specific Graves’ disease marker, thereby excluding patients with toxic nodules, 
thyroiditis, or non-thyroidal illness. By employing a landmark regression approach, 
we eliminated treatment time bias and additionally provided a clinically relevant time-
point from which to evaluate primary therapy. Our study limitation is that the 
retrospective design could have introduced bias from undocumented confounders 
such as smoking, orbitopathy, physician treatment preference, patient compliance 
with thionamides, and unrecorded exposure to thyroid hormone excess. However, 
our adjustments for comorbidity and biochemical characteristics would to some 
extent have adjusted for these confounders. In keeping with conventional practice, 
patients with more severe baseline disease received radioiodine, but it is unlikely 
that this influenced our results given that both radioiodine-treated groups had similar 
baseline features yet strikingly divergent outcomes. Lastly, thyroid tests were 
missing in a proportion of patients. However, we minimised potential bias from this 
using principled imputation methods and robust sensitivity checks. Ultimately, 
potential confounders will only be fully addressed in well-designed, randomised 
controlled trials which are yet to be undertaken.  
In conclusion, early and intensive control of hyperthyroidism in Graves’ disease is 
associated with improvements in long-term cardiovascular morbidity and mortality 
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regardless of therapy modality. Greater emphasis should now be placed on ensuring 
prompt elimination of hyperthyroidism and maintenance of a normal thyroid status in 
the management of Graves’ disease.  
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Primary therapy of Graves’ disease and cardiovascular morbidity and 
mortality: a linked-record cohort study  
Supplementary Appendix 
Supplementary Methods 
Modified Charlson Comorbidity Scores 
Comorbidity scores were derived using a modification of the Charlson Comorbidity 
Index (CCI) 1. Individual scores were calculated as the sum of weighted scores for 
each of 17 disease conditions identified from hospital admission data using ICD-10 
codes for secondary diagnosis fields (DIAG2-DIAG14) 2,3 (supplementary table 1).  
Laboratory assays 
Between January 1998 and April 2004 TSH receptor antibodies (TRAbs) were 
measured with a 2nd generation radioimmunoassay (RIA) based on inhibition of 
labelled TSH binding to TSH receptor coated tubes, RSR Limited, Cardiff 4,5. The 
assay reference ranges were: <1.0, negative, 1.0-1.5 borderline >1.5, positive with 
analytical range of 1—40 U/L, and lower detection limit of 0.33 U/L. The sensitivity of 
the assay was 92.0% with specificity of 100%. Between April 2004 and December 
2013, TRAbs were measured with a 2nd generation RIA which was also based on 
inhibition of radio-labelled TSH binding to TSH receptor coated tubes, B.R.A.H.M.S. 
TRAK human, Thermo Scientific 6. The assay reference ranges were: <1.0, negative, 
1.0-1.5 borderline, and >1.5, positive, with analytical range of 1—40 U/L, functional 
sensitivity of 1.0 +/- 0.2 U/L and analytical sensitivity of 0.3 U/L. The sensitivity of the 
assay was 98.8% with specificity of 99.6%. The assay principles, performance, and 
reference ranges for thyroid function tests (FT4 and TSH) are presented in 
supplementary table 2. To account for differences in assay methods, FT4 was 
transformed to multiples of the upper limit of the assay reference range (ULN) and 
TSH was categorised as low, normal or high-TSH according to the assay reference 
range. 
Restricted Cubic Spline Regression 
We modelled a potential non-linear relationship between the FT4 concentration at 
one year and mortality or MACE using restricted cubic spline regressions. Cubic 
splines allow flexible smooth transformations of the relationship between a 
quantitative covariate and an outcome 7. We used the mkspline co-mmand in Stata 
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to set 4 equally-spaced knots at percentiles 5, 35, 65 and 95 according to the 
recommendation by Harrell 8. Varying the positions of the knots did not significantly 
influence our estimates. The reference values were set at the FT4 assay upper limit 
(x 1.0). Predicted hazard ratios (HR) were derived from Cox regression models 
adjusted for age, gender, year of diagnosis, baseline TRAb concentration, and 
comorbidity. We used the xblc post-estimation package in Stata to plot the 
regression between FT4 and log HR for mortality/MACE. Models were fitted for the 
whole cohort and then stratified by treatment. P values for non-linearity were 
obtained using likelihood ratio tests. We also used cubic splines to model 
longitudinal change in FT4 concentration in the first year of treatment with cubic 
knots set at 0, 3, 6, 9, and 12 months.  
Missing data imputation 
Serial thyroid function tests were available for patients with Graves’ disease but not 
for the control population. Thyroid function tests were missing in 29% of patients. 
One-year TSH was available in 80% of patients with serial thyroid function tests 
equivalent to 57% of the eligible landmark cohort. All other variables had complete 
data. Missing thyroid tests were due to lack of electronic access and linkage of 
laboratory data to the SAIL databank from some laboratories at various study time 
segments. Where laboratory linkage occurred, thyroid tests were available in >90% 
of patients in clinics served by the laboratory, reducing the likelihood of confounding 
by data not missing at random.  
The characteristics of patients with missing and non-missing thyroid tests is shown in 
supplementary table 3. Patients with missing tests were older (49 vs 47 years) and 
missing tests were more frequent in patients treated with antithyroid drugs compared 
to radioiodine or surgery (37% vs 3% vs 16%, P<0.001). Patients with missing tests 
also had lower TRAb levels (median 5.8 vs 7.8 IU/L) but in logistic regression, the 
only factors associated with thyroid test missingness were older age (OR 1.01, 
95%CI 1.00, 1.02 per year increase in age) and treatment with antithyroid drugs (OR 
2.28, 95%CI 1.61, 3.23, antithyroid drugs vs radioiodine/Surgery). Missingness was 
not associated with sex, comorbidity, TRAB concentration, mortality or MACE. Thus, 
we assumed the data were not ‘Missing Completely at Random, (MCAR)’ but were 
‘Missing at Random, (MAR)’.  
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In the one-year TSH analysis we addressed missing tests using multiple variable 
imputation by chained equations 9. The imputation model comprised all predictor and 
outcome variables in the analysis. We generated 50 imputed datasets and fitted Cox 
proportional models within each dataset after which estimates were pooled 
according to Rubin’s rules 10. In sensitivity analysis we repeated the analysis using a 
complete case analysis which showed identical estimates to the imputation model 
(Supplementary figure 1). To exclude the possibility that missingness at one-year 
was associated with stable or worse disease control, we modelled two sensitivity 
scenarios in which a normal-TSH and a low-TSH at one-year were assumed for 
patients with serial TSH but missing one-year TSH. These scenarios gave similar 
results to the imputation model (data not shown).  
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   Treatment groups  
 Population controls All Patients  Antithyroid drugs Iodine-131 Thyroidectomy  
 n=16756 n=4189  n=3094  n=829  n=266  P for trend c 
Age, yrs       
 Mean + SD 48 + 16 48 + 16 48 + 16 50 + 16 39 + 13 <0·001 
 <20 204 (1·2) 51 (1·2) 37 (1·2) 6 (0·7) 8 (3·0) <0·001 
 20-29 2176 (13·0) 544 (13·0) 402 (13) 83 (10·0) 59 (22·2)  
 30-39 3420 (20·4) 855 (20·4) 626 (20·2) 138 (16·6) 91 (34·2)  
 40-49 3688 (22·0) 922 (22·0) 667 (21·6) 195 (23·5) 60 (22·6)  
 50-59 3240 (19·3) 810 (19·3) 601 (19·4) 184 (22·2) 25 (9·4)  
 60-69 2340 (14·0) 585 (14·0) 443 (14·3) 124 (15·0) 18 (6·8)  
 >70 1688 (10·1) 422 (10·1) 318 (10·3) 99 (11·9) 5 (1·9)  
Sex       
 Female 13656 (81·5) 3414 (81·5) 2527(81·7) 656 (79·1) 231 (86·8) 0·017 
 Male 3100 (18·5) 775 (18·5) 567 (18·3) 173 (20·9) 35 (13·2)  
Comorbidity        
 Absent 15453 (92·2) 3599 (85·9) 2647 (85·6) 715 (86·2) 237 (89·1) 0·263* 
 Present 1303 (7·8) 590 (14·1) 447 (14·4) 114 (13·8) 29 (10·9)  
TRAb IU/L — 6·9 (3·1, 16·8) 6·0 (2·8, 13·6) 11·3 (4·1, 26·4) 15·9 (5·8, 36·3)  <0·001 
Thyroid status       
 FT4, pmol/La — 31·8 + 22·0 29·5 + 19·7 36·2 + 25·4 36·5 + 25·6 <0·001 
 FT4 >40 pmol/La — 719 (24) 390 (20) 255 (32) 74 (33) <0·001 
Person years follow up 103374 25266 16481 6878 1907  
TABLE 1: Baseline characteristics of the whole cohort  
Data represents numbers (%), mean + SD, or median (interquartile range).  a, data available for 2962 patients, TRAb, TSH receptor antibody; c, P values are for trend 
across treatment categories. Patients and controls were matched for age· *Comorbidity was increased in patients compared to controls (P<0·001) 
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Outcome 
Number of cases (%)  
Graves’ disease 
N=4189 
Controls a 
N=16756 Crude HR (95% CI) P value Adjusted HR (95 CI) b P value 
All-cause Mortality 228 (5·4) 765 (4·6) 1·22 (1·05, 1·42) 0·008 1·23 (1·06, 1·42) 0·033 
MACEc 329 (7·9) 651 (3·9) 2·18 (1·91, 2·48) <0·001 2·47 (2·16, 2·81) <0·001 
Atrial Fibrillation 240 (5·7) 379 (2·3) 2·62 (2·23, 3·08) <0·001 2·67 (2·25, 3·15) <0·001 
Acute Myocardial Infarction 38 (0·9) 122 (0·7) 1·26 (0·87, 1·81) 0·220 1·22 (0·84, 1·76) 0·287 
Acute coronary syndrome 32 (0·8) 74 (0·4) 1·75 (1·15, 2·65) 0·008 1·65 (1·09, 2·51) 0·018 
Congestive Cardiac Failure 109 (2·6) 240 (1·4) 1·85 (1·47, 2·31) <0·001 1·78 (1·42, 2·23) <0·001 
Ischaemic Stroke 41 (1·0) 98 (0·6) 1·70 (1·17, 2·43) 0·005 1·60 (1·11, 2·30) 0·012 
Haemorrhagic Stroke 14 (0·3) 37 (0·2) 1·53 (0·83, 2·83) 0·175 1·50 (0·81, 2·78) 0·196 
Type 1 Diabetes 29 (0·7) 42 (0·3) 2·71 (1·68, 4·37) <0·001 2·53 (1·56, 4·08) <0·001 
Type 2 Diabetes 170 (4·1) 474 (2·8) 1·46 (1·23, 1·74) <0·001 1·39 (1·16, 1·66) <0·001 
All Diabetes 199 (4·8) 516 (3·1) 1·57 (1·33, 1·85) <0·001 1·46 (1·24, 1·71) <0·001 
Thyroid Cancer 8 (0·2) 5 (0·0) 6·52 (2·13, 19·93) <0·001 6·67 (2·18, 20·41) 0·001 
Breast Cancer 38 (0·9) 143 (0·9) 1·08 (0·76, 1·55) 0·442 1·06 (0·74, 1·52) 0·798 
TABLE 2: Hazard ratios for mortality, MACE, and other events  
a Controls are matched for age and sex b Hazard ratios are derived from Cox proportional models adjusted for age, sex and comorbidity, c MACE, major adverse 
cardiovascular event comprising acute myocardial infarction, congestive cardiac failure, ischaemic cerebrovascular accident, or death  
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FIGURE 1: Study flow chart 
TRAb, TSH receptor antibody; ATD, Antithyroid Drugs; RAI, radioactive iodine; RAI-Group-A, radioiodine with hyperthyroidism 
control by one-year, and RAI-Group-B, radioiodine without hyperthyroidism control by one-year; *Numbers add up to 171 for 170 
patients because one patient had thyroidectomy and died in the first year.  
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FIGURE 2: Kaplan Meier curves for mortality or MACE   
Kaplan Meier curves for cumulative mortality (panels A-D) or MACE (panels E-H) in the whole cohort and by primary treatment. ATD, patients who 
received antithyroid drugs alone in the first one-year, RAI-Group-A, radioiodine with hyperthyroidism control by one-year, and RAI-Group-B, radioiodine 
without hyperthyroidism control by one-year. HR, Hazard ratios derived from Cox regression models adjusted for age, sex, and comorbidity. 
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SUPPLEMENTARY FIGURE 1: Hazard ratios for mortality or MACE by one-year TSH, complete case analysis 
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. Analysis was conducted in all patients and in 
treatment subgroups according to treatment in the first-year with antithyroid drugs (ATD) or radioactive iodine (RAI). P-int, P values for 
interaction with treatment group. Results are obtained from a complete case analysis 
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SUPPLEMENTARY FIGURE 2: FT4 profile post-diagnosis  
Longitudinal	profile	of	FT4	concentrations	after	diagnosis	according	to	treatment	groups.	FT4	is	in	multiples	of	the	
upper	limit	of	the	reference	range	(X	ULN);	ATD,	antithyroid	drugs,	RAI-Grp-A,	radioiodine	with	control	of	
hyperthyroidism	by	12	months,	RAI-Grp-B,	radioiodine	without	control	of	hyperthyroidism	by	12	months	
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  FT4, pmol/L TSH, mU/L 
Laboratory Assay method, platform Reference Interval CV (%) Reference Interval CV (%) 
Cardiff and Vale      
 Jan 1998 - May 2011 CCIA, ADVIA Centaur, Bayer1 9·8–23·1 2·31 at 13·9 pmol/L 0·35 - 5·50 2·44 at 5·65 mU/L 
 May 2011 - Jan 2013 CMIA, Abbott ARCHITECT2  9·0 –19·1* <10 at all levels 0·30 - 4·40 <10 at all levels 
Cwm Taf (1)      
 Jan 1998 - March 2007 CCIA, IMMULITE 2000, DPC3  10·3–24·5 <10 at all levels 0·4 - 4·0 <5·0 at all levels 
 March 2007 - Dec 2013 ECLIA, Roche E-1704 10·3–24·5 8·2 at 8·2 pmol/L 0·4 - 4·0 2·4 at 6·67 mU/L 
Cwm Taf (2)      
 Jan 1995 – April 2011 CCIA, ADVIA Centaur, Bayer1 10·0-25·0 <10 at all levels 0·35-5·50** <10 at all levels 
 April 2011-Sept 2012 CCIA, ADVIA Centaur, Bayer1 10·0-25·0 <10 at all levels 0·35-5·50 <10 at all levels 
 Sept 2012-Dec 2013 ECLIA, Roche E-1704 10·3–24·5 8·2 at 8·2 pmol/L 0·4 - 4·0 2·4 at 6·67 mU/L 
Aneurin Bevan (1)  
 
    
                                            1998-2006 CCIA, IMMULITE 2000, DPC3  11·5–22·7 <10 at all levels 0·4 - 4·0 <5 at all levels 
 2006-2013 CMIA, Abbott ARCHITECT2  9·0–19·1 4·8% at 23·3 pmol/L 0·30 - 4·40 4·1% at 26·8 mU/L 
Aneurin Bevan (2)       
  1998—2000 MEIA, Abbott Axsym2  9·0–19·1 4·6 at 15·4 pmol/L 0·30 - 4·40 4·9 at 2·8 mU/L 
 2000—2006 CCIA, ADVIA Centaur, Bayer1 9·8–23·1 <10 at all levels 0·35 - 5·50 <10 at all levels 
 2007—2013 CMIA, Abbott ARCHITECT2 9·0–19·1 <10 at all levels 0·30 - 4·40 <10 at all levels 
Supplementary Table 1: Thyroid hormone assays  
CV, coefficient of variation; CCIA, competitive chemiluminescent immunoassay, CMIA, chemiluminescent microparticle immunoassay; ECLIA, 
electrochemiluminescence immunoassay; MEIA, Microparticle Enzyme Immunoassay; 1. Bayer Diagnostics, Newbury, UK; 2. 	Abbott Diagnostics, Maidenhead, 
Berks, UK; 3. Diagnostics Product Corporation, Llanberis, Wales; 4. Roche Diagnostics GmbH, Mannheim, Germany, *from January to December 2013 the 
reference range for this assay was changed to 9.2—21.0 pmol/L, **from September 2009 to April 2011, reference range for this assay was 0.3-6.0 mU/L  
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  Condition ICD-10 diagnosis codes Score 
Acute myocardial infarction I21, I22, I252 1 
Congestive heart failure I50 1 
Peripheral vascular disease I71, I790, I739, R02, Z958, Z959 1 
Cerebral vascular disease I60, I61, I62, I63, I65, I66, G450, G451, G452, G458, G459, G46, I64, G454, I670, 
I671, I672, I674, I675, I676, I677, I678, I679, I681, I682, I688, I69 
1 
Dementia F00, F01, F02, F051 1 
Pulmonary disease J40, J41, J42, J44, J43, J45, J46, J47, J67, J44, J60, J61, J62, J63, J66, J64, J65 1 
Connective tissue disease M32, M34, M332, M053, M058, M059, M060, M063, M069, M050, M052, M051, M353 1 
Peptic ulcer disease K25, K26, K27, K28 1 
Liver disease K702, K703, K73, K717, K740, K742, K746, K743, K744, K745 1 
Diabetes E109, E119, E139, E149, E101, E111, E131, E141, E105, E115, E135, E145 1 
Diabetes with complications E102, E112, E132, E142, E103, E113, E133, E143, E104, E114, E134, E144 2 
Hemiplegia or paraplegia G81, G041, G820, G821, G822 2 
Renal disease N03, N052, N053, N054, N055, N056, N072, N073, N074, N01, N18, N19, N25 2 
Cancer C0, C1, C2, C3, C40, C41, C43, C45, C46, C47, C48, C49, C5, C6, C70, C71, C72, 
C73, C74, C75, C76, C81, C82, C83, C84, C85, C883, C887, C889, C900, C901, C91, 
C92, C93, C940, C941, C942, C943, C945, C947, C95, C96 
2 
Metastatic cancer C77, C78, C79, C80 3 
Severe liver disease K729, K766, K767, K721 3 
HIV B20, B21, B22, B23, B24 6 
Supplementary Table 2: Modified Charlson Comorbidity Scores  
Reference 2,3 
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 Patients with available thyroid tests Patients with missing thyroid tests 
 All patients  Medical therapy Iodine-131 Thyroidectomy P for trend, 
treatment 
groups a 
All patients P value, 
missing vs non-
missing b 
 
n=2969  n=1950  n=796   n=223  n=1220 
Age, yrs        
 Mean + SD 47 + 16 46 + 16 50 + 16 39 + 13 <0·001 49 + 16 <0.001 
 <20 42 (1·4) 29 (1·5) 6 (0·8) 7 (3·1) <0·001 9 (0.7)  
 20-29 409 (13·8) 278 (14·3) 81 (10·2) 50 (22·4)  135 (11.1)  
 30-39 630 (21·2) 424 (21·7) 133 (16·7) 73 (32·7)  225 (18.4)  
 40-49 669 (22·5) 426 (21·9) 191 (24·0) 52 (23·3)  253 (20.7)  
 50-59 550 (18·5) 360 (18·5) 170 (21·4) 20 (9·0)  260 (21.3)  
 60-69 390 (13·1) 252 (12·9) 120 (15·1) 18 (8·1)  195 (16.0)  
 >70 279 (9·4) 181 (9·3) 95 (11·9) 3 (1·4)  143 (11.7)  
Sex        
 Female 2422 (81·6) 1596 (81·9) 633 (79·5) 193 (86·5) 0·050 992 (81.3) 0.841 
 Male 547 (18·4) 354 (18·2) 163 (20·5) 30 (13·5)  228 (18.7)  
Comorbidity         
 Absent 2564 (86·4) 1678 (86·1) 688 (86·4) 198 (88·8) 0·532 1035 (84.9) 0.198 
 Present 405 (13·6) 272 (13·9) 108 (13·6) 25 (11·2)  185 (15.2)  
TRAb IU/L 7·8 (3·2, 18·4) 6·4 (2·9, 14·0) 11·4 (4·2, 27·0) 16·4 (5·6, 37·5)  <0·001 5.8 (2.75, 12.9) <0.001 
Thyroid status        
 FT4, pmol/L 31·8 + 22·0 29·5 + 19·7 36·2 + 25·4 36·5 + 25·6 <0·001 —  
 FT4 >40 
pmol/L 
719 (24) 390 (20) 255 (32) 74 (33) <0·001 —  
Missing tests 1220 (29) 1144 (37) 33 (4) 43 (16) <0.001 —  
Supplementary Table 3: Baseline characteristics in patients with missing and non-missing thyroid function tests  
Data represents numbers (%), mean + SD, or median (interquartile range).  TRAb, TSH receptor antibody; a, P values are for trend across treatment 
categories in patients with thyroid tests. b, P values are for difference between missing and non-missing tests.  
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 ATD RAI-Group-A  RAI-Group-B P value  
Number (%) 3587 (89%) 250 (6%) 182 (5%)  
Age     
 Mean + SD 46·9 + 15·8 52·6 + 15·0 52·9 + 15·8 <0·001a, b 
 Range 18-92 19-88 20-92  
Gender     
 Male 642 (17·9%) 55 (22·0%) 41 (22·5%) 0·089 
 Female 2945 (82·1%) 195 (78·0%) 141 (77·5%)  
Comorbidity     
 Present 485 (13·5%) 35 (14·0%) 30 (16·5%) 0·728 
 Absent 3102 (86·5%) 215 (86·0%) 152 (83·5%)  
TRAbs, U/L 6·7 (3, 15·8)  11·2 (4·1, 26·6)  11·4 (4·4, 26·1)  <0·001a, b 
Radioiodine therapy     
 Dose, Mbq - 555 (546, 563) 555 (544, 566) 0·984d 
 Days from diagnosis to treatment - 108 (53, 178) 188 (88, 302) <0·001 d 
FT4, pmol/L      
 Baseline  31·2 + 21·8 35·2 + 25·2 34·8 + 21·7 <0·003a, b 
 12 months 17·4 + 9·3 15·9 + 7·3 21·5 + 10·6 <0·001a, b, c 
 Baseline – 12 months  16·1 + 23·0 21·1 + 26·9 13·9 + 21·3 <0·001b, c 
TSH at 12 months, mU/L     
 Low 770 (39·6%) 44 (18·9%) 84 (64·6%) <0·001 a, c 
 Normal 905 (46·5%) 41 (17·7%) 36 (27·7%)  
 High 272 (13·9%) 147 (63·4%) 10 (7·7%)  
Supplementary Table 4: Characteristics of patients in the one-year landmark cohort  
a ATD vs RAI-Group-A, b ATD vs RAI-Group-B, c RAI-Group-A vs RAI-Group-B; ANOVA with pairwise comparisons with Tukey’s test; d 
RAI-Group-A vs RAI-Group-B, Kruskal Wallis; data is in numbers (%), mean + standard deviation, or median (interquartile range). Excluded 
patients who had surgery in the first 12 months (n=78) or <12 months survival (n=89). 
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 All-Cause Mortality MACE 
 Events/Total, N HR (95% CI) P value Events/Total, N HR (95% CI) P value 
Whole cohort       
 ATD 145/3527 1·00 (Ref)  176/3384 1·00 (Ref)  
 RAI-Group-A 13/236 0·47 (0·27, 0·83) 0·009 17/224 0·49 (0·30, 0·81) 0·005 
 RAI-Group-B 21/174 1·52 (0·96, 2·42) 0·083 21/159 1·49 (0·94, 2·35) 0·089 
No comorbidities       
 ATD 82/3047 1·00 (Ref)  118/2982 1·00 (Ref)  
 RAI-Group-A 4/201 0·20 (0·07, 0·56) 0·002 7/195 0·25 (0·12, 0·54) 0·001 
 RAI-Group-B 13/146 1·45 (0·80, 2·63) 0·195 16/137 1·68 (0·99, 2·84)                0·052 
Age>50 yrs       
 ATD 129/1502 1·00 (Ref)  152/1387 1·00 (Ref)  
 RAI-Group-A 11/137 0·43 (0·23, 0·79) 0·007 15/127 0·46 (0·27, 0·79)  0·005 
 RAI-Group-B 19/96 1·52 (0·93, 2·48) 0·102 17/84 1·36 (0·82, 2·25) 0·236 
Age<50 yrs                                                                          
 ATD 16/2025 1·00 (Ref)  24/1997 1·00 (Ref)  
 RAI-Group-A 2/99 1·04 (0·23, 4·79) 0·963 2/97 0·74 (1·70, 3·18) 0·680 
 RAI-Group-B 2/78 1·36 (0·31, 6·09) 0·691 4/75 2·32 (0·79, 6·78) 0·125 
Supplementary Table 5: Mortality and MACE by primary treatment: excluding pregnant patients  
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. 	Analysis	was	conducted	in	all	patients	and	in	subgroups	
according	to	treatment	in	the	first-year. ATD, Antithyroid drugs, RAI-Group-A, radioiodine treatment with control of hyperthyroidism, RAI-Group-B, 
radioiodine treatment without control of hyperthyroidism   
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 All-Cause Mortality MACE 
 Events/Total, N HR (95% CI) P value Events/Total, N HR (95% CI) P value 
Whole cohort       
 ATD 142/3353 1·00 (Ref)  166/3215 1·00 (Ref)  
 RAI-Group-A 13/229 0·46 (0·26, 0·82) 0·009 17/218 0·50 (0·30, 0·83) 0·007 
 RAI-Group-B 21/166 1·53 (0·96, 2·44) 0·071 19/151 1·38 (0·86, 2·33) 0·184 
No comorbidities       
 ATD 82/2903 1·00 (Ref)  114/2841 1·00 (Ref)  
 RAI-Group-A 4/197 0·20 (0·07, 0·54)  0·002 7/192 0·25 (0·12, 0·54) 0·001 
 RAI-Group-B 13/139 1·44 (0·79, 2·60) 0·119 15/130 1·62 (0·94, 2·77)                                  0·082
Age>50 yrs       
 ATD 126/1408 1·00 (Ref)  142/1297 1·00 (Ref)  
 RAI-Group-A 11/131 0·42 (0·22, 0·78) 0·006 15/121 0·48 (0·28, 0·82) 0·007 
 RAI-Group-B 19/89 1·53 (0·94, 2·50) 0·089 15/77 1·23 (0·72, 2·11) 0·443 
Age<50 yrs                                                                              
 ATD 16/1945 1·00 (Ref)  24/1918 1·00 (Ref)  
 RAI-Group-A 2/98 1·02 (0·22, 4·69) 0·984 2/97 0·72 (1·67, 3·11) 0·660 
 RAI-Group-B 2/77 1·38 (0·31, 6·16) 0·673 4/74 2·31 (0·79, 6·74) 0·126 
Supplementary Table 6: Mortality and MACE by primary treatment: excluding patients with borderline TRAbs  
Patients with borderline TRAbs (1.0-1.5 IU/L) were excluded. HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. 	
Analysis	was	conducted	in	all	patients	and	in	subgroups	according	to	treatment	in	the	first-year. ATD, Antithyroid drugs, RAI-Group-A, radioiodine 
treatment with control of hyperthyroidism, RAI-Group-B, radioiodine treatment without control of hyperthyroidism   
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 Model 1 Model 2 
 HR (95% CI) P value HR (95% CI) P value 
Age, years a 1·09 (1·08, 1·10) <0·001 1·09 (1·08, 1·10) <0·001 
Sex     
 Male 1·00 Ref 1·00 Ref 
 Female  0·57 (0·43, 0·76) <0·001 0·65 (0·47, 0·90) 0·010 
Co-morbidity     
 Absent 1·00 Ref 1·00 Ref 
 Present 3·07 (2·29, 4·13) <0·001 3·30 (2·36, 4·63) <0·001 
Year of diagnosis b 0·68 (0·58, 0·79) <0·001 0·63 (0·54, 0·79) <0·001 
Baseline TRAb c  1·15 (0·99, 1·32) 0·069 1·14 (0·96, 1·35) 0·144 
Thyroid hormones     
 Baseline FT4 d  — — 0·99 (0·99, 1·00) 0·474 
 Baseline TSH  — —   
  TSH 0.1—0·4 mU/L   1·00 Ref 
  TSH <0·1 mU/L   0·99 (0·95, 1·02) 0·384 
 Serial FT4 d — — 1·40 (1·11, 1·77) 0·005 
 Serial TSH     
  Normal/High — — 1·00 Ref 
  Low — — 1·00 (0·66, 1·54) 0.980 
Treatment     
 ATD 1·00 Ref  1·00 Ref 
 RAI without hyperthyroidism control 0·91 (0·67, 1·25) 0·571 0·97 (0·70, 1·36) 0·863 
 RAI with hyperthyroidism control 0·26 (0·08, 0·82) 0·022 0·27 (0·09, 0·87) 0·028 
 Thyroidectomy 0·60 (0·15, 2·44) 0·472 0·33 (0·05, 2·39) 0·272 
Supplementary Table 7: Multivariable analysis for all-Cause mortality  
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. Model 1, all patients, n=4189; Model 2, patients with 
thyroid function tests, n=2969; Serial thyroid hormones and treatment were set as time-dependent covariates. Patients contributed person-years 
of treatment from diagnosis to radioiodine treatment or thyroidectomy (ATD), following radioiodine to control of hyperthyroidism (RAI without 
hyperthyroidism control), following radioiodine and control of hyperthyroidism (RAI with hyperthyroidism control), and following thyroidectomy 
(thyroidectomy).   a, HR per 5-year increase in age; b, HR per 5-year increase in diagnosis year, c, HR per 10 IU/L increase in TRAb 
concentration, d, HR per 10 pmol/L increase in FT4 concentration 
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 Model 1 Model 2 
 HR (95% CI) P value HR (95% CI) P value 
Age, years  1·08 (1·07, 1·09) a <0·001 1·08 (1·07, 1·09) a <0·001 
Sex     
 Male 1·00 Ref 1·00 Ref 
 Female  0·56 (0·44, 0·71) <0·001 0·61 (1·07, 1·09) <0·001 
Co-morbidity     
 Absent 1·00 Ref 1·00 Ref 
 Present 2·91 (2·28, 3·72)  <0·001 2·95 (2·22, 3·91) <0·001 
Year of diagnosis  0·75 (0·67, 0·85) b <0·001 0·74 (0·64, 0·86) b <0·001 
Baseline TRAb  1·04 (0·93, 1·17) c 0·493 1·06 (0·92, 1·22) c 0·404 
Thyroid hormones     
 Baseline FT4  — — 0·99 (0·99, 1·00) d 0·618 
 Baseline TSH  — —   
  TSH 0.1—0·4 mU/L   1·00 Ref 
  TSH <0·1 mU/L   0·99 (0·96, 1·01) 0·317 
 Serial FT4 — — 1·52 (1·09, 1·94) d 0·007 
 Serial TSH     
  Normal/High — — 1·00 Ref 
  Low — — 1·00 (0·89, 1·78) 0.990 
Treatment     
 ATD 1·00 Ref 1·00 Ref 
 RAI without hyperthyroidism control 1·02 (0·78, 1·34) 0·857 1·08 (·081, 1·43) 0·601 
 RAI with hyperthyroidism control 0·44 (0·20, 0·94) 0·033 0·45 (0·21, 0·96) 0·040 
 Thyroidectomy 0·35 (0·09, 1·43) 0·144 0·19 (0·03, 1·40) 0·103 
Supplementary Table 8: Multivariable analysis for MACE  
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. Model 1, all patients, n=4189; Model 2, patients with 
thyroid function tests, n=2969; Serial thyroid hormones and treatment were set as time-dependent covariates. Patients contributed person-years 
of treatment from diagnosis to radioiodine treatment or thyroidectomy (ATD), following radioiodine to control of hyperthyroidism (RAI without 
hyperthyroidism control), following radioiodine and control of hyperthyroidism (RAI with hyperthyroidism control), and following thyroidectomy 
(thyroidectomy).   a, HR per 5-year increase in age; b, HR per 5-year increase in diagnosis year, c, HR per 10 IU/L increase in TRAb 
concentration, d, HR per 10 pmol/L increase in FT4 concentration 
